News | May 29, 2022
JBCL rebrands as JB
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
The integration and transition of the brands are expected to be completed by June 2022.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Subscribe To Our Newsletter & Stay Updated
